ALLOAllogene Therapeutics, Inc.
$1.40+3.7% 1Y
$1.40
$1.0552 weeks$3.06
ALLO in its own filings
ALLO's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
150
Events found in the filings · across 581 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 2, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 11, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Restatement admitted (non-reliance)past_3y
- 2024-02-16
- SEC comment-letter activity14 occurrences
- 2024-04-23
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.Director or officer change · Form 8-K
- Aug 12, 2026Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update.Earnings release · press release
- Jun 22, 2026On June 22, 2026, the Company filed a prospectus supplement (the "Prospectus Supplement") with the Securities and Exchange Commission relating to sales of shares of its common stock having an aggregate offering price of up to $135.0 million to be sold pursuant to a certain Sales Agreement, dated November 5, 2019, as …Shareholder vote results · Form 8-K
- May 28, 2026On May 28, 2026, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang …Director or officer change · Form 8-K
- May 13, 2026On May 12, 2026, Allogene Therapeutics, Inc. (“Allogene”) entered into (i) a Termination Agreement (the “Termination Agreement”) with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. (collectively, the “Overland Parties”) and (ii) a Second Amended and Restated Shareholders’ Agreement (the …Material agreement entered · Form 8-K
- Apr 15, 2026On April 14, 2026, we entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of …Other event · Form 8-K
- Apr 13, 2026On April 13, 2026, Allogene Therapeutics, Inc. (the “Company”) announced the commencement of a proposed underwritten public offering of its common stock.Other event · Form 8-K
- Apr 13, 2026On April 13, 2026, Allogene Therapeutics, Inc. (“Allogene” or the “Company”) announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (“cema-cel”) in first-line (“1L”) consolidation for large B-cell lymphoma (“LBCL”)Other event · Form 8-K
- Mar 12, 2026Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial.Earnings release · press release
- Nov 6, 2025Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update.Earnings release · press release
- Oct 14, 2025On September 26, 2025, Factor Bioscience Inc. (“Factor”) filed a complaint in the United States District Court for the District of Delaware against our gene-editing technology licensor, Cellectis S.A., and its affiliate Cellectis, Inc. (collectively, “Cellectis”), alleging that Cellectis’s TALEN-based gene-editing …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…